These accumulating data suggest that the inhibition of NPC1L1-dependent cholesterol uptake by ezetimibe may be a suitable therapeutic target for treatment of not only hypercholesterolemia but also broader aspects of metabolic disorders in patients with type 2 diabetes and/or metabolic syndrome (Figure 5). This evidence concerns the gene NPC1L1 and metabolic disease.